For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, ...

Among individuals with achalasia, male sex, older age and prior esophageal Candida infection increased risk for esophageal ...

The Phase III MATTERHORN trial has delivered groundbreaking results, demonstrating that AstraZeneca’s IMFINZI® (durvalumab) ...

Researchers at ASCO's annual meeting also discussed the importance of repeat biopsies to assess HER2 status after first-line ...

Cancers of the esophagus and gastroesophageal (GEJ) junction cancer differ from those in the rest of the stomach. They share epidemiological characteristics with and often originate from segments of ...

Discover why GERD without esophagitis causes severe symptoms despite normal endoscopy results. Learn 8 hidden mechanisms ...

Patients with newly diagnosed gastric or gastroesophageal junction (GEJ) cancer who received the PD-L1 inhibitor durvalumab ...

Thus, it can withstand intra-esophageal pressure when it passes through the esophagus. This capsule robot can enter the stomach for targeted drug releasing without leaking liquid drugs along the path.